The Director of clinical research and testing Office having regard to articles 8 and 9 of legislative decree July 30, 1999, # 300, bearing the "reform of the Government, in accordance with art. 11 March 15, 1997, law No. 59 "; Visto l'art. September 30, 2003, 48 of Decree-Law n. 269, containing "urgent provisions to promote the development and correction of the trend of public finances", converted, with amendments, into law no 326 November 24, 2003, which established the Italian medicines agency; Having regard to the September 20, 2004, Decree No. 245 of the Minister of health, in consultation with the Ministers of economy and finance and civil service: "regulation laying down rules on the organisation and the functioning of the Italian Medicines Agency, in accordance with art. 48, paragraph 13 of the Decree-Law No 269 September 30, 2003, converted, with amendments, by law November 24, 2003, # 326 "March 29, 2012, as well as modified by Decree No. 53 of the Minister of health, in consultation with the Ministers for public administration and simplification and of economy and finance:" amendments to the regulation and functioning of Agenzia italiana del farmaco (AIFA), in art. 17, paragraph 10, of the Decree-Law July 6, 2011, n. 98, converted, with amendments, by law No 111 July 15, 2011 "; Having regard to regulation for the organisation, administration and the organisation of the Italian medicines agency staff published in the Gazzetta Ufficiale-serie generale n. 254 of October 31, 2009; Having regard to the Legislative Decree March 30, 2001, # 165 on "general rules on labour sort employed by public administrations" and s; Having regard to act July 15, 2002, # 145, containing "Provisions for the reorganization of the State leadership and to foster the exchange of experiences and the interaction between the public and private sectors"; Having regard to determination no. 1348 of November 12, 2014, with which the Director-General of the Italian Medicines Agency gave the the local coordinator Sandra dott.ssa Petraglia pre-authorization and the post of Director of the Office of research and clinical trial; Having regard to the Legislative Decree of April 24, 2006, n. 219 on "implementation of Directive 2001/83/EC (and subsequent amending directives) on the Community code relating to medicinal products for human use, as well as of Directive 2003/94/EC" and s; View the determination # 1418 of November 26, 2014 concerning the partial update to determines May 18, 2011 concerning the updating of the list of medicinal products established by Commission's decision only (CUF) of July 20, 2000, payable to the sole responsibility of the national health service, under the law of December 23, 1996, n. 648 (atazanavir), whose abstract was published in the official journal-General series No. 291 of December 16, 2014; Considering that such determination should be rectification, by mistake the material contained therein; Having regard to official acts;
Causes: Art. 1 Corrigendum determination # 1418 of November 26, 2014 it is rectified in the following terms, determining # 1418 of November 26, 2014 on the partial update to determines May 18, 2011 concerning the updating of the list of medicinal products established by Commission's decision only (CUF) of July 20, 2000, payable to the sole responsibility of the national health service, under the law of December 23, 1996, # 648 (atazanavir), whose abstract was published in the official journal-General series No. 291 of December 16, 2014 : annex excerpt from the minutes of the October 23, 2014 21, 22 and CTS Office research and clinical trial is deemed ' not published '.